Advanced Science (May 2025)

Autologous Peripheral Vγ9Vδ2 T Cell Synergizes with αβ T Cell Through Antigen Presentation and BTN3A1 Blockade in Immunotherapy of Cervical Cancer

  • Min Wu,
  • Jian Liu,
  • Liting Liu,
  • Yifan Yang,
  • Hong Liu,
  • Long Yu,
  • Haihong Zeng,
  • Shuo Yuan,
  • Ruiyi Xu,
  • Hangyu Liu,
  • Han Jiang,
  • Shen Qu,
  • Liming Wang,
  • Ying Chen,
  • Jingyu Wang,
  • Yuwei Zhang,
  • Shan He,
  • Ling Feng,
  • Junyan Han,
  • Wanjiang Zeng,
  • Hui Wang,
  • Yafei Huang

DOI
https://doi.org/10.1002/advs.202401230
Journal volume & issue
Vol. 12, no. 18
pp. n/a – n/a

Abstract

Read online

Abstract New treatment strategies are urgently needed for patients with advanced cervical cancer (CC). Here, a synergistic anti‐CC effect of a novel combinatorial immunotherapy with adoptively transferred autologous Vγ9Vδ2 T cells and αβ T cells is shown. The pivotal role of both circulating and tumor‐infiltrating Vγ9Vδ2 T cells in anti‐CC immunity is uncovered. Importantly, autologous Vγ9Vδ2 T cells show a synergistic anti‐CC effect with αβ T cells not only through killing tumor directly, but also by promoting the activation and tumoricidal activity of syngeneic αβ T cells through antigen presentation, which can be further boosted by conventional chemotherapy. Moreover, Vγ9Vδ2 T cells can restore the tumoricidal function of αβ T cell through competitively binding to BTN3A1, a TCR‐Vγ9Vδ2 ligand on CC cells upregulated by IFN‐γ derived from activated αβ T cell. These findings uncover a critical synergistic effect of autologous Vγ9Vδ2 T cells and αβ T cells in immunotherapy of CC and reveal the underlying mechanisms.

Keywords